DIBI (IV)
Complicated Urinary Tract Infections (cUTI)
Key Facts
About Fe Pharmaceuticals
Fe Pharmaceuticals is a private, preclinical-stage biotech leveraging a novel platform of iron-binding polymers to treat diseases driven by iron dysregulation. Its lead candidate, DIBI, is designed to sequester iron from pathogens and rapidly dividing cells, with initial applications targeting antimicrobial-resistant infections, sepsis, and cancer. The company's approach represents a unique, non-antibiotic mechanism to address growing global threats like AMR, with a versatile pipeline spanning inhaled, IV, oral, and topical formulations.
View full company profileAbout Fe Pharmaceuticals
Fe Pharmaceuticals is a private, preclinical-stage biotech leveraging a novel platform of iron-binding polymers to treat diseases driven by iron dysregulation. Its lead candidate, DIBI, is designed to sequester iron from pathogens and rapidly dividing cells, with initial applications targeting antimicrobial-resistant infections, sepsis, and cancer. The company's approach represents a unique, non-antibiotic mechanism to address growing global threats like AMR, with a versatile pipeline spanning inhaled, IV, oral, and topical formulations.
View full company profileTherapeutic Areas
Other Complicated Urinary Tract Infections (cUTI) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cefepime/Enmetazobactam | Allecra Therapeutics | Phase 3 |